2505 Dalton Avenue
70 articles with TSO3 Inc.
TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Thursday, March 28, 2019, to discuss its financial results for the fourth quarter and full year ended December 31, 2018.
TSO3 Inc. announced that during its fourth fiscal quarter ending December 31, 2018, the Company received an order for the 100th unit of its industry-leading STERIZONE® VP4 Sterilizer
American Journal of Infection Control publishes TSO3 study on terminal sterilization of duodenoscopes
TSO3 Inc. announces today that the results of the Company's clinical in-use and simulated use testing of the terminal sterilization of duodenoscopes have been published in the American Journal of Infection Control.
TSO3 Inc. reported financial results for the third fiscal quarter ended September 30, 2018.
TSO3 Inc. announced that the Company has been awarded a sole-source contract relating to a low temperature sterilizer Request for Proposal (or tender) in the Province of Quebec for its STERIZONE® VP4 Sterilizers.
TSO3 Inc. was named the winner of the South Carolina Chamber of Commerce's SC Branded Product Innovation Award.
TSO3 Inc. announced today that it has appointed Mr. Martin J. Madden to the Company's board of directors.
Cutting-edge system sterilizes duodenoscopes with low-temperature device
TSO3 Inc. reported financial results for the second fiscal quarter ended June 30, 2018.
TSO3 Announces Closing of US$20 million Financing with Courage Capital to Commercialize the STERIZONE® VP4 Sterilizer and Support Getinge Transition
Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization Technology
TSO3 Inc. joins with Altru® Health System in announcing the landmark U.S. terminal sterilization of long, flexible gastrointestinal endoscopes
TSO3 Announces the Vote Results from its Annual Meeting of the Shareholders and the Appointment New Chairperson
TSO3 Inc. (TSX: TOS), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated April 3, 2018, were elected as directors of TSO3. In addition, all other proposals submitted by management were approved.
TSO3 to Report First Quarter 2018 Results and Hold Annual Meeting of Shareholders on Wednesday, May 9, 2018
TSO3 Inc. will hold a conference call on Wednesday, May 9, 2018 to discuss its financial results for the first quarter ended March 31, 2018.
Studies demonstrate the efficacy of the STERIZONE® VP4 Sterilizer for inactivation of prions.
TSO3 Inc. announced that the Company's Chief Science Officer, Brad Catalone, will moderate an educational session during the 60th annual International Association of Healthcare Central Service Material Management (IAHCSMM) Congress, being held in Phoenix, Arizona April 29 to May 2, 2018.
TSO3 Inc. reported financial results for the fourth quarter and year ended December 31, 2017.
The Company included data on modified leak test experiments, testing to confirm lack of fluid ingress occurring under the distal end cap of the devices, as well as real-world data from market research commissioned by TSO3 reflecting the actual use-life of duodenoscopes.
TSO3 today provided an update on its 2017 operating activities.
The Sales and Repurchase Agreement allows the Company to sell its STERIZONE VP4 Sterilizers and associated products and services directly into the United States and Canada.
The Company now believes that the information it has provided to the Regulators addresses the majority of items listed within the initial AI request.